Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies | 16.09.2022

Date: 16th September 2022 Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen exclusive access to Soteria® and Phloral® technologies for oral colonic delivery of therapeutic proteins, deriving from Elasmogen’s soloMER™ platform, for an undisclosed target for treatment of Crohn’s disease and ulcerative […]